CapsoVision (NASDAQ:CV) Announces Earnings Results

CapsoVision (NASDAQ:CV) issued its quarterly earnings results on Thursday. The company reported $0.02 earnings per share for the quarter, FiscalAI reports. The business had revenue of $3.92 million for the quarter.

Here are the key takeaways from CapsoVision’s conference call:

• Strong commercial momentum with ~15% full‑year revenue growth and Q4 revenue of $3.9M, an installed base of >161,000 patients imaged, and accelerating adoption in hospital systems (hospital customers +87% in Q4).
• CapsoCam Colon Gen 2 is progressing quickly—roughly >500 (close to 600) of a target ~800 patients enrolled across 11 U.S. sites, with a planned 510(k) submission in Q3 2026 and management targeting FDA clearance ~Q1 2027 and commercial launch in H2 2027.
• Company advanced its AI strategy by submitting a 510(k) for an AI‑assisted reading module (end of 2025) and highlights a cloud image repository intended to improve diagnostic accuracy and reduce physician reading time.
• Pancreatic UGI screening work is early stage: a ~60–90 patient study to define diagnostic scoring begins in Q2 2026 after constructive FDA engagement, but clinical validation and regulatory outcomes remain uncertain.
• Financials show rising investment and burn—Q4 operating expenses increased to $9.4M (up $3.1M) due to sensor and clinical development, but the subsequent $14M private placement (price $4.88/share) bolsters liquidity beyond the reported year‑end cash of $10.1M.

CapsoVision Trading Down 8.9%

NASDAQ:CV opened at $7.53 on Friday. CapsoVision has a 12 month low of $3.43 and a 12 month high of $15.37. The stock has a market capitalization of $352.73 million and a price-to-earnings ratio of -3.44. The firm has a fifty day simple moving average of $5.55 and a two-hundred day simple moving average of $6.22.

Hedge Funds Weigh In On CapsoVision

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp grew its stake in shares of CapsoVision by 340.7% in the 4th quarter. State Street Corp now owns 85,929 shares of the company’s stock valued at $919,000 after buying an additional 66,429 shares during the period. Geode Capital Management LLC boosted its holdings in CapsoVision by 34.1% in the fourth quarter. Geode Capital Management LLC now owns 154,264 shares of the company’s stock worth $1,649,000 after acquiring an additional 39,231 shares in the last quarter. Citadel Advisors LLC acquired a new stake in CapsoVision in the third quarter valued at approximately $115,000. Millennium Management LLC acquired a new stake in CapsoVision in the fourth quarter valued at approximately $163,000. Finally, Virtu Financial LLC bought a new stake in shares of CapsoVision during the fourth quarter valued at approximately $128,000.

Analysts Set New Price Targets

CV has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a research note on Monday, December 29th. Wall Street Zen upgraded CapsoVision to a “hold” rating in a report on Saturday, January 10th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.00.

CapsoVision Company Profile

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.